NEWS RELEASE

NEUTRISCI ANNOUNCES INTERNATIONAL DISTRIBUTION AGREEMENT AND INITIAL ORDERS

Vancouver, British Columbia – September 7, 2016 – NeutriSci International Inc. (the "Company" or "NeutriSci") (TSX-V: NU / Frankfurt: 1N9), the innovator and pioneer behind neuenergy™, is pleased to announce its first European distribution agreement with Soletek GmbH, Germany ("Soletek").

Under this agreement, Soletek (www.soletek.de) has agreed to act as exclusive distributor for neuenergy™ in Germany and Austria. Management of Soletek has more than 25 years' experience and long standing business connections with many of Europe's largest retailers such as Metro Group (including Real and CC) Fegro Selgros, Edeka (including Marktkauf), Rossmann, DM, Müller and TV home shopping channels HSE24, QVC as well as Channel 21.

Neuenergy™ is a revolutionary energy tab designed to deliver enhanced focus and mental clarity with no sugar, no calories and no crash associated with typical energy products. Neuenergy™ contains a unique patented combination of blueberries (pterostilbene) and naturally derived caffeine.

Global sales of energy drinks hit €38.2 billion last year and will be worth €53.4bn in 2020 with Germany and the rest of Western Europe representing €7.2bn according to Euromonitor International. The energy supplement industry has been growing profitably for years as other once-popular beverages have declined. Two of the three leading companies are privately owned, which limits options for investors who want direct exposure to this category.

Mr. Glen Rehman, President of NeutriSci International, stated, "This new distribution agreement represents a major step forward for NeutriSci and neuenergy. This European partnership will provide consumers local access to neuenergy from trusted retailers in Germany and Austria. As of August 31st, NeutriSci has shipped its third batch of neuenergy to Germany. We expect subsequent monthly orders to follow beginning in Q4/2016. We couldn't be more excited about the long term potential of this agreement for both the direct revenue and the further distribution agreements that will ultimately follow from other retailers. We see this partnership as an anchor in our global retail distribution program; driving strong revenues and establishing international brand recognition."

On Behalf of the Board of Directors of

NEUTRISCI INTERNATIONAL INC.
Glen Rehman
President
NeutriSci International Inc.
Tel: (403) 264-6320
Email: grehman@neutrisci.com

For investor relations inquiries:
Skanderbeg Capital Advisors
Mario Vetro
O: 604-687-7130 x105

C: 778-846-9970
Mario@skanderbegcapital.com

About NeutriSci International Inc.

NeutriSci specializes in the innovation, production and formulation of nutraceutical products. Established in 2009, NeutriSci has focused on the development of several breakthrough nutraceutical products with an initial focus on areas such as heart and cholesterol health, sleep deprivation therapies, immune defense as well as men's prostate and sexual health.

Neuenergy™ is a revolutionary energy tab designed to deliver enhanced focus and mental clarity with no sugar, no calories and no crash associated with typical energy products. To find out more about neuenergy™, please visit www.getneuenergy.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

Statements in this press release have not been evaluated by the Food and Drug Administration. Products or ingredients are not intended to diagnose, treat, cure or prevent any disease.